27698544|t|Esomeprazole - or rabeprazole -based triple therapy eradicated Helicobacter pylori comparably regardless of clarithromycin susceptibility and CYP2C19 genotypes
27698544|a|The aim of this study was to assess the efficacy of esomeprazole -based triple therapy compared with rabeprazole -based triple therapy according to CYP2C19 genotype and clarithromycin susceptibility status for first-line eradication therapy of Helicobacter pylori (H. pylori) in Japan. We enrolled 219 H. pylori - infected patients, and randomly allocated patients to the EAC group (esomeprazole 20 mg, clarithromycin 200 mg, amoxicillin 750 mg for one week, with all drugs given twice daily) or RAC group (rabeprazole 10 mg, clarithromycin 200 mg, amoxicillin 750 mg for one week, with all drugs given twice daily). The H. pylori eradication rate according to the PP analyses was 75.0% (95% CI: 65.2-82.8%) in the EAC group and 71.4% (95% CI: 61.4-79.1%) in the RAC group. There were no statistically significant differences. The eradication rates of the clarithromycin -resistant /- sensitive strains were, respectively, 45.0% (95% CI: 30.7-60.2%)/98.0% (95% CI: 88.7-100%) in the EAC group and 39.5% (95% CI: 25.6-55.3%)/93.5% (95% CI: 81.9-98.4%) in the RAC group. The eradication rate of the clarithromycin - sensitive strains was significantly higher than that of the resistant strains in both groups. In conclusion, EAC and RAC therapies show a comparable efficacy regardless of the CYP2C19 genotype and clarithromycin susceptibility status in Japan.
27698544	0	12	Esomeprazole	T103	UMLS:C0937846
27698544	18	29	rabeprazole	T103	UMLS:C0378482
27698544	44	51	therapy	T058	UMLS:C0087111
27698544	63	82	Helicobacter pylori	T007	UMLS:C0079488
27698544	108	122	clarithromycin	T103	UMLS:C0055856
27698544	142	149	CYP2C19	T017	UMLS:C1332828
27698544	176	181	study	T062	UMLS:C2603343
27698544	212	224	esomeprazole	T103	UMLS:C0937846
27698544	239	246	therapy	T058	UMLS:C0087111
27698544	261	272	rabeprazole	T103	UMLS:C0378482
27698544	287	294	therapy	T058	UMLS:C0087111
27698544	308	315	CYP2C19	T017	UMLS:C1332828
27698544	329	343	clarithromycin	T103	UMLS:C0055856
27698544	381	423	eradication therapy of Helicobacter pylori	T058	UMLS:C0559761
27698544	425	434	H. pylori	T007	UMLS:C0079488
27698544	439	444	Japan	T082	UMLS:C0022341
27698544	462	471	H. pylori	T007	UMLS:C0079488
27698544	543	555	esomeprazole	T103	UMLS:C0937846
27698544	563	577	clarithromycin	T103	UMLS:C0055856
27698544	586	597	amoxicillin	T103	UMLS:C0002645
27698544	628	633	drugs	T103	UMLS:C0013227
27698544	667	678	rabeprazole	T103	UMLS:C0378482
27698544	686	700	clarithromycin	T103	UMLS:C0055856
27698544	709	720	amoxicillin	T103	UMLS:C0002645
27698544	751	756	drugs	T103	UMLS:C0013227
27698544	781	790	H. pylori	T007	UMLS:C0079488
27698544	825	836	PP analyses	T062	UMLS:C0936012
27698544	1016	1030	clarithromycin	T103	UMLS:C0055856
27698544	1016	1041	clarithromycin -resistant	T038	UMLS:C0860039
27698544	1055	1062	strains	T007	UMLS:C0004611
27698544	1257	1271	clarithromycin	T103	UMLS:C0055856
27698544	1284	1291	strains	T007	UMLS:C0004611
27698544	1334	1351	resistant strains	T038	UMLS:C0860039
27698544	1395	1404	therapies	T058	UMLS:C0087111
27698544	1450	1457	CYP2C19	T017	UMLS:C1332828
27698544	1471	1485	clarithromycin	T103	UMLS:C0055856
27698544	1511	1516	Japan	T082	UMLS:C0022341